Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.

Tim SchmächeJuliane FohgrubAnna KlimovaKarin LaaberStephan DrukewitzFelix MerbothAlexander HennigTherese SeidlitzFriederike HerbstFranziska BaenkeAnne-Marlen AdaThomas GroßCarina WenzelClaudia R BallChristian PraetoriusThomas SchmidtBarbara Ringelband-SchillingRonald KoschnyAlbrecht StenzingerIngo RoederDirk JaegerSebastian ZeissigThilo WelschDaniela AustHanno GlimmGunnar FolprechtJürgen WeitzGeorg M HaagDaniel E Stange

Published in: Molecular cancer (2024)

In vitro drug testing of EGC PDOs has a high predictive accuracy in classifying patients' histological response to neoadjuvant FLOT treatment. Taking into account the high rate of successful PDO expansion from biopsies, the definition of a threshold that allows treatment stratification paves the way for an interventional trial exploring PDO-guided treatment of EGC patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
randomized controlled trial
clinical trial
squamous cell carcinoma
study protocol
patient reported outcomes
open label
patient reported
adverse drug
electronic health record